Animal models of schizophrenia: A critical review

Journal of Psychiatry and Neuroscience

Volumn 26, Issue 5, 2001, Pages 395-410

  Marcotte, Eric R ^a   Pearson, Debra M ^a   Srivastava, Lalit K ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN REGION; CLINICAL FEATURE; DISEASE COURSE; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN; BRAIN MAPPING; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; NEUROTRANSMITTER AGENTS; RESEARCH; SCHIZOPHRENIA;

EID: 0035694654     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (275)

1. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism
2. Schizophrenia as a progressive disorder: Relations to EEG, CT, neuropathological and other evidence
3. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited
4. Is schizophrenia a lifetime disorder of brain plasticity, growth and aging?
5. Schizophrenia as failure of hemispheric dominance for language
6. To model a psychiatric disorder in animals. Schizophrenia as a reality test
7. Animal models of psychiatric disorders
8. The emergence of modern neuroscience: Some implications for neurology and psychiatry
9. Schizophrenia and temporal lobe epilepsy. A neuropsychological analysis
10. Research on schizophrenia in the NIMH laboratory of psychology and psychopathology, 1954-1987
11. Symptoms, signs, and diagnosis of schizophrenia
12. Descriptive psychopathology
13. The varied outcomes of schizophrenia
14. The heterogeneous course of schizophrenia
15. Outcome of schizophrenia: The Madras longitudinal study
16. Gender differences in schizophrenia. Results of a follow-up study from India
17. The genetics of schizophrenia: A current, genetic-epidemiologic perspective
18. The genetics of schizophrenia. Current knowledge and future directions
19. At issue: Genes, experience, and chance in schizophrenia - Positioning for the 21st century
20. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia
21. The pharmacology of latent inhibition as an animal model of schizophrenia
22. Animal neuropharmacology and its prediction of clinical response
23. Amphetamine models of paranoid schizophrenia: An overview and elaboration of animal experimentation
24. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis
25. Dopamine receptors and the dopamine hypothesis of schizophrenia
26. The dopamine theory revisited
27. Simple schizophrenia, negative symptoms, and prefrontal hypodopaminergia
28. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
29. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
30. Imaging dopamine transmission in schizophrenia. A review and meta-analysis
31. The phenomenology of experimentally induced amphetamine psychosis - Preliminary observations
32. Toxicity of drug abuse - Amphetamine designer drugs (ecstasy): Mental effects and consequences of single dose use
33. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia
34. Provocative tests with psychostimulant drugs in schizophrenia
35. Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls
36. Multiple receptors for dopamine
37. Brain dopamine receptors: A primer on their current status, basic and clinical
38. Dopamine receptor diversity: Molecular and pharmacological perspectives
39. Molecular characteristics of mammalian dopamine receptors
40. Antipsychotic drug doses and neuroleptic/dopamine receptors
41. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
42. 2 receptors
43. 2 densities and the schizophrenic brain
44. 2 dopamine receptors in drug-naive schizophrenics
45. 2 receptors by dopamine in schizophrenia
46. 3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study
47. 1 DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia
48. 4 receptors
49. 4 receptors in schizophrenia?
50. The neuropathology of schizophrenia. A critical review of the data and their interpretation
51. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis
52. Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat
53. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
54. Prestimulus effects on human startle reflex in normals and schizophrenics
55. Sensorimotor gating and schizophrenia. Human and animal model studies
56. Gating and habituation of the startle reflex in schizophrenic patients
57. Dopamine in schizophrenia: A review and reconceptualization
58. 2 receptors to neuronal circuits in human brain: Insights into schizophrenia
59. Gating of information flow within the limbic system and the pathophysiology of schizophrenia
60. Two syndromes of schizophrenia as one pole of the continuum of psychosis: A concept of the nature of the pathogen and its genomic locus
61. Abnormal mental states induced by phencyclidine as a model of schizophrenia
62. Neurochemistry and neuropharmacology of schizophrenia
63. Excitatory amino acids and phencyclidine drugs
64. Recent advances in the phencyclidine model of schizophrenia
65. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
66. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
67. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
68. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
69. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
70. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach
71. The glutamatergic dysfunction hypothesis for schizophrenia
72. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine
73. Glutamate receptor dysfunction and schizophrenia
74. Long-term potentiation in the amygdala: A mechanism for emotional learning and memory
75. Evidence relating human verbal memory to hippocampal N-methyl-D-aspartate receptors
76. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
77. Evidence of glutamatergic deficiency in schizophrenia
78. Amino acid patterns in schizophrenia: Some new findings
79. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
80. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
81. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia
82. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?
83. A two-process theory of schizophrenia: Evidence from studies in post-mortem brain
84. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine
85. Increased startle responding in rats treated with phencyclidine
86. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats
87. Characterization of the inhibition of excitatory amino acid-induced neurotransmitter release in the rat striatum by phencyclidine-like drugs
88. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat
89. Automation of the social interaction test by a video-tracking system: Behavioural effects of repeated phencyclidine treatment
90. Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: Comparisons to other psychomotor stimulants
91. Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo
92. Phencyclidine (PCP): Effects of acute and chronic administration on EEG activities in the rhesus monkey
93. Behavioral and neurochemical alterations following repeated phencyclidine administration in rats with neonatal ventral hippocampal lesions
94. Behavioral effects of chronic phencyclidine in monkeys
95. The effects of acute and chronic phencyclidine on schedule-controlled behavior in the squirrel monkey
96. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: A new model of schizophrenia
97. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
98. 2A (serotonin2A) receptor gene in the aetiology, pathophysiology and pharmacotherapy of schizophrenia
99. LSD
100. 1A receptors may play a role in hallucinogenesis
101. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
102. 2A receptor T102C polymorphism and schizophrenia
103. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia
104. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia
105. The role of serotonin in the pathophysiology and treatment of schizophrenia
106. 2A receptor density abnormality in the cortex of schizophrenic patients studied with PET
107. Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review
108. 2A receptors and clozapine response
109. Startle habituation and sensorimotor gating in schizophrenia and related animal models
110. Behavioral studies of hallucinogenic drugs in animals: Implications for schizophrenia research
111. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice
112. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain
113. 3 receptors in schizophrenia: A postmortem study of the amygdala
114. 3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia
115. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia
116. Augmentation of clozapine therapy with ondansetron
117. Acute and chronic LSD effects on rat startle: Data supporting an LSD - Rat model of schizophrenia
118. Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: Reversal by haloperidol
119. Functional and anatomical aspects of prefrontal pathology in schizophrenia
120. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia
121. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia
122. From neuropathology to neurodevelopment
123. Reduced GABA uptake sites in the temporal lobe in schizophrenia
124. A receptor binding in superficial layers of cingulate cortex in schizophrenics
125. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia
126. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
127. Psychopathology and the question of neurodevelopmental or neurodegenerative disorder
128. Strong inference, theory testing, and the neuroanatomy of schizophrenia
129. Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease?
130. Regional brain volume change over the life-time course of schizophrenia
131. Dopaminergic mechanisms in idiopathic and drug-induced psychoses
132. Duration of psychosis and outcome in first-episode schizophrenia
133. Excitatory amino acids and neuropsychiatric disorders
134. Neuroleptics and the natural course of schizophrenia
135. Early intervention for schizophrenia: Can the course of the illness be altered?
136. Subtype progression and pathophysiologic deterioration in early schizophrenia
137. Lateral cerebral ventricular enlargement in chronic schizophrenia
138. Malformations of the nervous system
139. Is schizophrenia a neurodevelopmental disorder?
140. Implications of normal brain development for the pathogenesis of schizophrenia
141. Schizophrenia: A neuropathological perspective
142. Advancing a neurodevelopmental origin for schizophrenia
143. Schizophrenia
144. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
145. Neurodevelopmental schizophrenia: The rediscovery of dementia praecox
146. A neurodevelopmental approach to the classification of schizophrenia
147. Minor physical anomalies in schizophrenia
148. High-risk research in schizophrenia: A summary of what has been learned
149. Infants at risk for schizophrenia: Sequelae of a genetic neurointegrative defect. A review and replication analysis of pandysmaturation in the Jerusalem Infant Development Study
150. Borna disease virus and schizophrenia
151. Detection of borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay
152. A viral-anatomical explanation of schizophrenia
153. Viruses, schizophrenia, and bipolar disorder
154. Effects of perinatal anoxia on the acute locomotor response to repeated amphetamine administration in adult rats
155. Obstetric complications and the risk of schizophrenia: A longitudinal study of a national birth cohort
156. Fetal neural development and adult schizophrenia: An elaboration of the paradigm
157. The problem of obstetrical complications and schizophrenia
158. Influence of perinatal factors on the nucleus accumbens dopamine response to repeated stress during adulthood: An electrochemical study in the rat
159. Long-term reciprocal changes in dopamine levels in prefrontal cortex versus nucleus accumbens in rats born by Caesarean section compared to vaginal birth
160. Birth insult increases amphetamine-induced behavioral responses in the adult rat
161. Responses to stress and novelty in adult rats born vaginally, by cesarean section or by cesarean section with acute anoxia
162. Transient birth hypoxia increases behavioral responses to repeated stress in the adult rat
163. Genetic factors modulate effects of C-section birth on dopaminergic function in the rat
164. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence
165. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism
166. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats
167. Mesocorticolimbic dopaminergic network: Functional and regulatory roles
168. Persistent elevations in dopamine and its metabolites in the nucleus accumbens after mild subchronic stress in rats with ibotenic acid lesions of the medial prefrontal cortex
169. Ibotenic acid lesions of medial prefrontal cortex augment swim-stress-induced locomotion
170. Effects of ibotenic acid lesion of the medial prefrontal cortex on dopamine agonist-related behaviors in the rat
171. Effect of ibotenic acid lesions of the medial prefrontal cortex on amphetamine-induced locomotion and regional brain catecholamine concentrations in the rat
172. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat
173. Do forebrain structures compete for behavioral expression? Evidence from amphetamine-induced behavior, microdialysis, and caudate-accumbens lesions in medial frontal cortex damaged rats
174. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats
175. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other
176. 2 receptors in the heightened locomotion induced by direct and indirect dopamine agonists in rats with hippocampal damage: An animal analogue of schizophrenia
177. Dorsal hippocampal lesion does not affect dopaminergic indices in the basal ganglia
178. Hippocampal modulation of nucleus accumbens: Behavioral evidence from amphetamine-induced activity profiles
179. Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolltes in the nucleus accumbens and prefrontal cortex in the rat
180. Heterogeneity of the hippocampus: Effects of subfield lesions on locomotion elicited by dopaminergic agonists
181. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia
182. Progressive neurodegeneration after intracerebroventricular kainic acid administration in rats: Implications for schizophrenia?
183. Kainic acid decreases hippocampal neuronal number and increases dopamine receptor binding in the nucleus accumbens: An animal model of schizophrenia
184. Kainic acid lesions enhance locomotor responses to novelty, saline, amphetamine, and MK-801
185. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging
186. Left globus pallidus abnormality in never-medicated patients with schizophrenia
187. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics
188. Quantitative neuroanatomy in schizophrenia. A controlled magnetic resonance imaging study
189. Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients: A pilot magnetic resonance imaging study
190. Regulation of prepulse inhibition by ventral pallidal projections
191. Functional development of the prefrontal cortex in early life and the problem of neuronal plasticity
192. Abnormal reinnervation as a basis for schizophrenia: A hypothesis
193. 2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex
194. Enhanced nucleus accumbens dopamine and plasma corticosterone stress responses in adult rats with neonatal excitotoxic lesions to the medial prefrontal cortex
195. Excitotoxic lesions of the rat medial prefrontal cortex. Effects on abnormal behaviors associated with neonatal hippocampal damage
196. 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus
197. Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol
198. Neonatal ventral hippocampal lesions attenuate the nucleus accumbens dopamine response to stress: An electrochemical study in the adult rat
199. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat
200. Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats
201. Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens
202. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine
203. Disruption of latent inhibition in rats with postnatal hippocampal lesions
204. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood
205. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: Quantitative and qualitative analysis
206. Memory and socioemotional behavior in monkeys after hippocampal damage incurred in infancy or in adulthood
207. Neonatal insult to the hippocampal region and schizophrenia: A review and a putative animal model
208. Delayed neuronal loss after administration of intracerebroventricular kainic acid to preweanling rats
209. Sex differences in "cognitive" regions of the rat brain
210. Ibotenic acid lesions of the medial prefrontal cortex potentiate FG-7142-induced attenuation of exploratory activity in the rat
211. The determinants of stress-induced activation of the prefrontal cortical dopamine system
212. Development of the dopaminergic innervation in the prefrontal cortex of the rat
213. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion
214. Cellular changes in rat brain areas associated with neonatal hippocampal damage
215. Attenuated extracellular dopamine levels after stress and amphetamine in the nucleus accumbens of rats with neonatal ventral hippocampal damage
216. Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: Behavioral and in vivo microdialysis studies
217. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine
218. Enhancement of postsynaptic sensitivity to dopaminergic agonists induced by neonatal hippocampal lesions
219. Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: Lack of changes after a neonatal bilateral lesion of the ventral hippocampus
220. Age and other factors in motor recovery from precentral lesion in monkeys
221. Plasticity in the neocortex: Mechanisms underlying recovery from early brain damage
222. Sparing of function after neonatal frontal lesions correlates with increased cortical dendritic branching: A possible mechanism for the Kennard effect
223. Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models
224. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain
225. Nerve-terminal proteins: To fuse to learn
226. Synaptic vesicle phosphoproteins and regulation of synaptic function
227. Addiction, dopamine, and the molecular mechanisms of memory
228. Age-related abnormalities in expression of mRNAs encoding synapsin 1A, synapsin 1B, and synaptophysin in the temporal cortex of schizophrenics
229. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
230. An analysis of synapsin II, a neuronal phosphoprotein, in postmortem brain tissue from alcoholic and neuropsychiatrically ill adults and medically ill children and young adults
231. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia
232. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'
233. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity
234. Linkage and family-based association study of schizophrenia and the synapsin III locus that maps to chromosome 22q13
235. Mutational analysis of the synapsin III gene on chromosome 22q12-q13 in schizophrenia
236. Synapsin III gene polymorphisms and schizophrenia
237. Neural cell adhesion molecules of the immunoglobulin superfamily: Role in axon growth and guidance
238. Molecular cues that guide the development of neural connectivity
239. Adhesion molecules and inherited diseases of the human nervous system
240. NCAM is essential for axonal growth and fasciculation in the hippocampus
241. Removal of polysialic acid-neural cell adhesion molecule induces aberrant mossy fiber innervation and ectopic synaptogenesis in the hippocampus
242. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains
243. Genetic deletion of a neural cell adhesion molecule variant (N-CAM-180) produces distinct defects in the central nervous system
244. NCAM-180 knockout mice display increased lateral ventricle size and reduced prepulse inhibition of startle
245. Genetics of neuronal migration in the cerebral cortex
246. A new view of early cortical development
247. Reeler: New tales on an old mutant mouse
248. A decrease of reelin expression as a putative vulnerability factor in schizophrenia
249. Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice
250. Engrailed-1 and netrin-1 regulate axon pathfinding by association interneurons that project to motor neurons
251. Growth-cone attraction to netrin-1 is converted to repulsion by laminin-1
252. Directed growth of early cortical axons is influenced by a chemoattractant released from an intermediate target
253. Netrin-3, a mouse homolog of human NTN2L, is highly expressed in sensory ganglia and shows differential binding to netrin receptors
254. Altered midline axon pathways and ectopic neurons in the developing hypothalamus of netrin-1-and DCC-deficient mice
255. Ephrins and their receptors: A repulsive topic?
256. Eph receptors and ephrins: Effectors of morphogenesis
257. Eph receptors and ephrins in neural development
258. Expression of EphA4, ephrin-A2 and ephrin-A5 during axon outgrowth to the hindlimb indicates potential roles in pathfinding
259. A role for the Eph ligand ephrin-A3 in entorhino-hippocampal axon targeting
260. Selective inhibition of spinal cord neurite outgrowth and cell survival by the Eph family ligand ephrin-A5
261. Specification of distinct dopaminergic neural pathways: Roles of the Eph family receptor EphB1 and ligand ephrin-B2
262. Topographic targeting and pathfinding errors of retinal axons following overexpression of ephrinA ligands on retinal ganglion cell axons
263. Modulation of EphA receptor function by coexpressed ephrinA ligands on retinal ganglion cell axons
264. Semaphorin-mediated neuronal growth cone guidance
265. Dissecting semaphorin signaling
266. Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections
267. Chemoattraction and chemorepulsion of olfactory bulb axons by different secreted semaphorins
268. Ectopic semaphorin-1a functions as an attractive guidance cue for developing peripheral neurons
269. Semaphorin 3A is a chemoattractant for cortical apical dendrites
270. Receptors for collapsin/semaphorins
271. Semaphorin signaling: A little less perplexin
272. Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families
273. Search for schizophrenia susceptibility genes